

Alexandra Schäfer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4674552/publications.pdf>

Version: 2024-02-01

49
papers

12,578
citations

109321

35
h-index

197818

49
g-index

70
all docs

70
docs citations

70
times ranked

20820
citing authors

#	ARTICLE	IF	CITATIONS
1	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. <i>Science Translational Medicine</i> , 2022, 14, eabj7125.	12.4	93
2	Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. <i>Science Translational Medicine</i> , 2022, 14, eabm3410.	12.4	49
3	A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection. <i>Science Immunology</i> , 2022, 7, eabo0226.	11.9	22
4	Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. <i>Nature Immunology</i> , 2022, 23, 960-970.	14.5	39
5	A Multitrait Locus Regulates Sarbecovirus Pathogenesis. <i>MBio</i> , 2022, 13, .	4.1	11
6	SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	55
7	Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection in Collaborative Cross mice. <i>PLoS Pathogens</i> , 2021, 17, e1009287.	4.7	22
8	SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. <i>Nature</i> , 2021, 591, 451-457.	27.8	320
9	Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. <i>Cell Reports Medicine</i> , 2021, 2, 100313.	6.5	56
10	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. <i>Cell Reports</i> , 2021, 36, 109450.	6.4	38
11	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. <i>Cell</i> , 2021, 184, 4203-4219.e32.	28.9	228
12	COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. <i>Immunity</i> , 2021, 54, 1869-1882.e6.	14.3	59
13	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. <i>Science</i> , 2021, 373, 991-998.	12.6	144
14	Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. <i>Nature</i> , 2021, 599, 465-470.	27.8	129
15	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. <i>Journal of Virology</i> , 2021, 95, e0097421.	3.4	12
16	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021, 184, 5432-5447.e16.	28.9	131
17	Dissecting strategies to tune the therapeutic potential of SARS-CoV-2â€“specific monoclonal antibody CR3022. <i>JCI Insight</i> , 2021, 6, .	5.0	34
18	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	283

#	ARTICLE	IF	CITATIONS
19	Stabilized coronavirus spike stem elicits a broadly protective antibody. <i>Cell Reports</i> , 2021, 37, 109929.	6.4	64
20	Immune predictors of mortality following RNA virus infection. <i>Journal of Infectious Diseases</i> , 2020, 221, 882-889.	4.0	10
21	Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. <i>Nature Communications</i> , 2020, 11, 222.	12.8	1,376
22	A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. <i>Nature</i> , 2020, 586, 560-566.	27.8	527
23	A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. <i>Cell</i> , 2020, 183, 169-184.e13.	28.9	446
24	High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models. <i>Cell</i> , 2020, 183, 429-441.e16.	28.9	100
25	A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. <i>Cell</i> , 2020, 183, 1070-1085.e12.	28.9	472
26	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. <i>Nature</i> , 2020, 586, 567-571.	27.8	1,153
27	Complex Genetic Architecture Underlies Regulation of Influenza-A-Virus-Specific Antibody Responses in the Collaborative Cross. <i>Cell Reports</i> , 2020, 31, 107587.	6.4	31
28	Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. <i>EBioMedicine</i> , 2020, 62, 103132.	6.1	77
29	SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. <i>Science</i> , 2020, 370, 1464-1468.	12.6	808
30	Potently neutralizing and protective human antibodies against SARS-CoV-2. <i>Nature</i> , 2020, 584, 443-449.	27.8	956
31	Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 29832-29838.	7.1	81
32	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. <i>Cell</i> , 2020, 183, 1367-1382.e17.	28.9	420
33	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. <i>DMM Disease Models and Mechanisms</i> , 2020, 13, .	2.4	46
34	A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. <i>Vaccines</i> , 2020, 8, 771.	4.4	61
35	SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. <i>Cell</i> , 2020, 182, 429-446.e14.	28.9	1,257
36	Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. <i>Cell Reports</i> , 2020, 32, 107940.	6.4	412

#	ARTICLE	IF	CITATIONS
37	An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	886
38	MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E1012-E1021.	7.1	142
39	Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform. <i>Journal of Virology</i> , 2018, 92, .	3.4	33
40	SARS-Like Coronavirus WIV1-CoV Does Not Replicate in Egyptian Fruit Bats (<i>Rousettus aegyptiacus</i>). <i>Viruses</i> , 2018, 10, 727.	3.3	21
41	Epigenetic Landscape during Coronavirus Infection. <i>Pathogens</i> , 2017, 6, 8.	2.8	96
42	Allelic Variation in the Toll-Like Receptor Adaptor Protein <i>Ticam2</i> Contributes to SARS-Coronavirus Pathogenesis in Mice. <i>G3: Genes, Genomes, Genetics</i> , 2017, 7, 1653-1663.	1.8	75
43	The effect of inhibition of PP1 and TNF α signaling on pathogenesis of SARS coronavirus. <i>BMC Systems Biology</i> , 2016, 10, 93.	3.0	58
44	Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection. <i>MBio</i> , 2015, 6, e00638-15.	4.1	390
45	Pathogenic Influenza Viruses and Coronaviruses Utilize Similar and Contrasting Approaches To Control Interferon-Stimulated Gene Responses. <i>MBio</i> , 2014, 5, e01174-14.	4.1	246
46	The SARS coronavirus papain like protease can inhibit IRF3 at a post activation step that requires deubiquitination activity. <i>Virology Journal</i> , 2014, 11, 209.	3.4	58
47	Systems approaches to coronavirus pathogenesis. <i>Current Opinion in Virology</i> , 2014, 6, 61-69.	5.4	12
48	The Role of the Blood-Brain Barrier during Venezuelan Equine Encephalitis Virus Infection. <i>Journal of Virology</i> , 2011, 85, 10682-10690.	3.4	59
49	Remdesivir Potently Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. <i>SSRN Electronic Journal</i> , 0, , .	0.4	15